Faries Mark B
John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.
Crit Rev Oncog. 2016;21(1-2):65-73. doi: 10.1615/CritRevOncog.2016017124.
The last few years have yielded exciting developments in immunotherapy for cancer. The promise of cancer immunotherapy has been well known for many years, but had generally produced limited or inconsistent benefit to patients. Intralesional therapies, which are in fact one of the oldest forms of immunotherapy, are also demonstrating benefits in the modern age. This review discusses the origins of intralesional immunotherapy and its underlying rationale. It also discusses the reemergence of this mode of therapy into the modern era, which is where Donald L. Morton, subject of this edition of the journal, plays a major role. The review also discusses current areas of investigation. Given the intuitive advantages of this strategy and the demonstrated, expanding areas of clinical responses, it is likely that intralesional immunotherapy will remain a useful component of cancer treatment into the future.
过去几年，癌症免疫疗法取得了令人振奋的进展。癌症免疫疗法的前景多年来已广为人知，但总体上给患者带来的益处有限且不一致。瘤内疗法实际上是最古老的免疫疗法形式之一，在现代也显示出了疗效。本综述讨论了瘤内免疫疗法的起源及其基本原理。它还探讨了这种治疗方式在现代的再度兴起，而本期杂志的主题人物唐纳德·L·莫顿在其中发挥了重要作用。该综述还讨论了当前的研究领域。鉴于这种策略的直观优势以及已证实的、不断扩大的临床反应领域，瘤内免疫疗法很可能在未来仍将是癌症治疗的一个有用组成部分。
